Alessandro Vannucchi, MD, is a Professor of Hematology and Director of the Hematology Department at the University of Florence, Florence, Italy. Alongside this, he is the Head at the Center for Research and Innovation in Myeloproliferative Neoplasms (CRIMM), Chair of the WP on Myeloproliferative Neoplasms of GIMEMA, Board Member of the International Working Group for Myelofibrosis Research and Treatment (IWG-MRT), National Coordinator of the Italian MYNERVA project, and a member of the Board of Directors of the Italian Society of Hematology.
After completing his medical degree at the University of Florence, Italy in 1980, Prof. Vannucchi worked in the Bone Marrow Transplant Unit in Florence, before joining the University of Florence in 2002. Prof. Vannucchi is currently on the Editorial Board of Blood for Haematologica, and has previously been an Editor for the Blood Cancer Journal and the New England Journal of Medicine. He is an active member of the Italian Society of Hematology, Italian Society of Experimental Hematology, American Society of Hematology, and the European Hematology Association.
Speaking on myeloproliferative neoplasms and molecular genetics of myeloid neoplasia
Prof. Vannucchi has been the Principal Investigator in over 50 clinical trials, primarily focusing on patients with myeloproliferative neoplasms (MPNs). More recently, Prof. Vannucchi has been researching the effects of the COVID-19 pandemic on patients with MPNs and other hematological malignancies, as well testing the safety and efficacy of multiple new treatments, such as ruxolitinib and fedratinib, for the treatment of MPN and myelofibrosis. Prof. Vannucchi is also the coordinator of the MYNERVA-GIMEA trial, which studies early intensification in FLT3-mutated acute myeloid leukemia (AML).